Our findings indicated that GP may be an effective drug in reducing the neuroinflammation of AD or even treat AD, and SOCS1 protein can be a potential therapeutic target for the treatment of microglial activation-induced neuroinflammatory disorders. The gene discussed is SOCS1; the disease is Alzheimer disease.